Overview

Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia

Status:
Unknown status

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find answers to the following questions: - What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? - What are the side effects of AQ4N when given according to this schedule? - How much AQ4N is in the blood at certain times after administration and how does the body get rid of the drug? - Will AQ4N help treat lymphoid cancer?

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Novacea

Treatments:

AQ4N